Table 3.

Scenario analyses: increased PCV20 uptake and decreased PCV20 effectiveness in 65-year-olds by race

	Incremental CE ratio (per QALY gained)
	Base case	Increased PCV20 uptake*	Decreased PCV20 relative effectiveness†
Black population
PCV20	$169,540	$169,538	$212,211
PCV15/PPSV23	$535,797	$5,738,000	$233,300
Non-Black population
PCV20	$210,529	$210,527	$273,373
PCV15/PPSV23	$728,423	$5,362,000	$298,468

CE cost-effectiveness, PCV15 15-valent pneumococcal conjugate vaccine, PCV20 20-valent pneumococcal conjugate vaccine, PPSV23 23-valent pneumococcal polysaccharide vaccine, QALY quality-adjusted life year

*10% absolute uptake increase with the one-vaccine PCV20 strategy compared to the two-vaccine PCV15/PPSV23 strategy

^†20% relative decrease in PCV20 effectiveness due to coverage degradation from multiple added serotypes